 Home > Active Ingredient News > Antitumor Therapy > 10-year data on Chinese women: Which early breast cancer patients undergoing breast-conserving surgery are more likely to relapse locally?

10-year data on Chinese women: Which early breast cancer patients undergoing breast-conserving surgery are more likely to relapse locally?

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

1 4 chain

3 4 inches

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

For early breast cancer (EBC), breast-conserving surgery (BCS) has been established as one of the treatment standards

At present, the risk of LRR in EBC patients is mainly assessed by baseline factors

Some clinicopathological risk factors, including younger onset, lobular histology, high grade, late manifestation, and specific molecular subtypes , have been shown to predict the increase in local recurrence rates after BCS and whole breast radiotherapy

This study aims to describe different patterns of LRR after BCS through population-based registration in large institutions

This single-center large-sample retrospective study conducted retrospective analysis of the data of 4325 women with early unilateral invasive breast cancer who were not treated with neoadjuvant treatment before breast-conserving surgery at the Fudan University Affiliated Cancer Hospital from 2006 to 2016

According to the type of recurrence and the recurrence-free interval, the recurrence mode is further analyzed

The median age at diagnosis of 4,325 patients was 49 years (17-99 years)

The univariate and multivariate associations between the clinicopathological variables and LRR are shown in Table 2

The ARR curve graph is shown in Figure 2

Figure 3 shows the OS curve after tumor resection

Table 3 shows the temporal and spatial characteristics of LRR, including recurrence type and recurrence time

Table 3 shows the temporal and spatial characteristics of LRR, including recurrence type and recurrence time
.
In the spatial location of 120 cases of LRR, 61.
8% (73/120) patients had ipsilateral intramammary recurrence, and 47 cases (39.
2%) had regional lymph node involvement
.
According to the above classification scheme, 37 cases of recurrence in the breast were classified as TR, 22 cases were classified as NP, and 14 cases could not be classified
.
The interval between breast recurrences in NP patients was longer than that in TR patients (62.
6 months vs.
39.
4 months, p; 0.
001)
.

Analysis of the time distribution of LRR after tumor resection showed that 60.
8% (73/120) of recurrence events occurred within 3 years after surgery, 25% (30/120) occurred within 3-5 years after surgery, and 14.
2% (17/120) ) Occurred 5 years after surgery
.
Considering the type of recurrence and the time of recurrence, there was no statistically significant difference in the distribution of IBTR and RNR in the time range (P = 0.
670; Table 3)
.
Patients with recurrence in the breast are more likely to have no distant metastasis, while patients with local recurrence tend to have SDM (P < 0.
001)
.

Considering the impact of tumor biology on the recurrence pattern, we conduct exploratory analysis based on molecular subtype classification
.

IRR most commonly occurs in HR-HER2+ tumors (7.
5%), while HR+HER2+ tumors are 6.
9%, triple-negative tumors are 4.
7%, and HR+HER2- tumors are 1.
2% (Figure 3D )
.
In the context of LRR, the HR-HER2+ subtype is more likely to have intramammary recurrence than the other three subtypes
.
However, there was no difference in RFI between recurrence types (Figure 4A, B)
.

In addition, we also explored the temporal patterns of LRR based on specific molecular subtypes
.
For HR-negative (HR-) tumors, there was a significant sharp rise 2 years after tumor resection, and the triple-negative group had a higher ARR
.
After that, the risk of HR-HER2+ and triple-negative groups quickly dropped to a lower level
.
For HR-positive (HR+) tumors, there is a delayed recurrence peak in the past 4 years after surgery, and the recurrence rate of HR+HER2+ tumors is higher
.
It is worth noting that the evening peak effect is clearly observed in the HR+HER2- subtype, which exhibits a continuous and increasing risk of recurrence, leaving a broad platform in the middle area, spanning about 4-7 years , Reaching a peak in about 9-10 years (Figure 4C)
.

In summary, for Chinese patients with early breast cancer, age, pathological stage, and molecular subtype are predictors of local regional recurrence
.
Patients with regional lymph node recurrence, short recurrence-free interval, and distant metastasis have poor survival outcomes
.
HER2-positive hormone receptor-negative breast cancer has a higher local regional recurrence rate, a higher intramammary recurrence rate, and a peak recurrence in the first 2 years after surgery
.

In general, the risk of LRR after BCS in Chinese EBC patients is generally low
.
Different recurrence patterns after tumor resection lead to different prognosis
.
The management of local recurrence should be fully individualized and adjusted according to the degree of disease, molecular characteristics of recurrence, and baseline clinical factors
.

In general, the risk of LRR after BCS in Chinese EBC patients is generally low
.
The risk of LRR after BCS in Chinese EBC patients is generally low
.
Different recurrence patterns after tumor resection lead to different prognosis
.
The management of local recurrence should be fully individualized and adjusted according to the degree of disease, molecular characteristics of recurrence, and baseline clinical factors
.
Different recurrence patterns after tumor resection lead to different prognosis
.
The management of local recurrence should be fully individualized and adjusted according to the degree of disease, molecular characteristics of recurrence, and baseline clinical factors
.
manage

Original source:

Qu et al.
Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.

Front.
Oncol.
, 30 August 2021 | https://doi.
org/10.
3389/fonc.
2021.
690658

Front.
Oncol.
, 30 August 2021 | https://doi.
org/10.
3389/fonc.
2021.
690658

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.